⌘K

Astena Holdings (8095) · InitiativeFirst stated

Overall optimization of the CDMO business through the absorption-type merger of スペラファーマ and 岩城製薬’s Sakura Plant

First written in FY2024. . Latest entry: FY2024.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

CDMO business optimisation through the absorption-type merger of スペラファーマ and 岩城製薬佐倉工場A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first

FY2024First statedAnnual report
「At a meeting of the Board of Directors held on 27 November 2024, we resolved to carry out an absorption-type merger in which our consolidated subsidiary スペラファーマ株式会社 would be the surviving company and our consolidated subsidiary Iwaki Pharmaceutical Sakura Plant Co., Ltd. would be the absorbed company.」
The Company resolved to conduct an absorption merger with 1 June 2025 as the business combination date. The purpose is to optimize the CDMO business as a whole in the fine chemicals business.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Astena Holdings yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.

Overall optimization of the CDMO business through the absorption-type merger of スペラファーマ and 岩城製薬’s Sakura Plant | Astena Holdings Co.,Ltd. (8095) | Komori